Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLA1 | P09884 | 1/20 | 0.72 |
| ▸ | CYP46A1 | Q9Y6A2 | 2/20 | 0.68 |
| ▸ | OSBP | P22059 | 3/20 | 0.64 |
| ▸ | USP2 | O75604 | 2/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.64 |
| ▸ | RORC | P51449 | 1/20 | 0.64 |
| ▸ | OSBP2 | Q969R2 | 1/20 | 0.64 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | NR1H3 | Q13133 | 4/20 | 0.57 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.56 |
| ▸ | NPC1L1 | Q9UHC9 | 2/20 | 0.56 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.55 |
| ▸ | GBA1 | P04062 | 2/20 | 0.55 |
| ▸ | UGCG | Q16739 | 2/20 | 0.55 |
| ▸ | GBA2 | Q9HCG7 | 2/20 | 0.55 |
| ▸ | STS | P08842 | 1/20 | 0.55 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.55 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2050989 | 1.00 | POLA1 (0.72) | POLA1CYP46A1OSBPUSP2LMNA | |
| SCHEMBL23070074 | 1.00 | POLA1 (0.72) | POLA1CYP46A1OSBPUSP2LMNA | |
| SCHEMBL10936315 | 1.00 | POLA1 (0.72) | POLA1CYP46A1OSBPUSP2LMNA | |
| Ammonia Solution, Strong SCHEMBL21817009 | 0.99 | POLA1 (0.71) | POLA1CYP46A1OSBPUSP2LMNA | |
| SCHEMBL7787257 | 0.92 | POLA1 (0.70) | POLA1CYP46A1OSBPUSP2LMNA | |
| SCHEMBL21177708 | 0.92 | POLA1 (0.70) | POLA1CYP46A1OSBPUSP2LMNA | |
| SCHEMBL10707535 | 0.92 | POLA1 (0.70) | POLA1CYP46A1OSBPUSP2LMNA | |
| SCHEMBL7787254 | 0.92 | POLA1 (0.70) | POLA1CYP46A1OSBPUSP2LMNA | |
| SCHEMBL29055425 | 0.92 | POLA1 (0.70) | POLA1CYP46A1OSBPUSP2LMNA | |
| SCHEMBL5888344 | 0.92 | POLA1 (0.68) | POLA1CYP46A1OSBPUSP2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119959397-A | Method for simultaneously detecting multiple cholesteric liquid crystal monomers in environmental medium | 暨南大学 | 2025-05-09 | — | — | CN | claimed |
| CN-112451682-A | Conjugates comprising self-degrading groups and methods relating thereto | 乐高化学生物科学股份有限公司 | 2021-03-09 | — | — | CN | claimed |
| CN-111065416-A | Hydrophilic linkers and conjugates thereof | 芬兰吉利科斯有限公司 | 2020-04-24 | — | — | CN | claimed |
| WO-2007143173-A2 | ATHEROGENIC COMPOSITIONS AND ANIMAL MODELS OF VASCULAR LESIONS | THE METHODIST HOSPITAL RESEARCH INSTITUTE (US) | 2007-12-13 | — | — | WO | claimed |
| US-12605342-B2 | Polymer-encapsulated drug particles | TONIC MEDICAL, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| US-12576037-B2 | Polymer-encapsulated drug particles | TONIC MEDICAL, INC. (US) | 2026-03-17 | — | — | US | disclosed |
| EP-4106828-B1 | POLYMER-ENCAPSULATED DRUG PARTICLES | TONIC MEDICAL INC (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-4678198-A2 | POLYMER-ENCAPSULATED DRUG PARTICLES | Tonic Medical, Inc. (US) | 2026-01-14 | — | — | EP | disclosed |
| US-20250352774-A1 | BALLOON CATHETER AND METHODS OF USING THE SAME | AIRIVER MEDICAL INC (US) | 2025-11-20 | — | — | US | disclosed |
| US-20250213491-A1 | POLYMER-ENCAPSULATED DRUG PARTICLES | TONIC MEDICAL, INC. | 2025-07-03 | — | — | US | disclosed |
| CN-119959397-A | Method for simultaneously detecting multiple cholesteric liquid crystal monomers in environmental medium | 暨南大学 | 2025-05-09 | — | — | CN | disclosed |
| US-20250082582-A1 | POLYMER-ENCAPSULATED DRUG PARTICLES | TONIC MEDICAL, INC. | 2025-03-13 | — | — | US | disclosed |
| EP-2507310-A2 | MODIFIED RUBBER COMPOSITIONS AND METHODS OF PREPARATION | Bridgestone Corporation (JP) | 2012-10-10 | — | — | EP | disclosed |
| WO-2011068846-A2 | MODIFIED RUBBER COMPOSITIONS AND METHODS OF PREPARATION | BRIDGESTONE CORPORATION (JP) | 2011-06-09 | — | — | WO | disclosed |
| US-7906147-B2 | superparamagnetic nanoparticles of iron coated with bilayer of molecules:(a) layer of oleic acid in direct contact with the iron particles; (b) a layer of Tween\"; bilayer of surface binding molecules and amphiphatic molecules; self-assembles; solubilizing; reducing toxicity; gold in MRI and tomography | NANOPROBES, INC. (US) | 2011-03-15 | — | — | US | disclosed |
| US-20080089836-A1 | superparamagnetic nanoparticles of iron coated with bilayer of molecules:(a) layer of oleic acid in direct contact with the iron particles; (b) a layer of Tween\"; bilayer of surface binding molecules and amphiphatic molecules; self-assembles; solubilizing; reducing toxicity; gold in MRI and tomography | NANOPROBES, INC. (US) | 2008-04-17 | — | — | US | disclosed |
| WO-2007143173-A2 | ATHEROGENIC COMPOSITIONS AND ANIMAL MODELS OF VASCULAR LESIONS | THE METHODIST HOSPITAL RESEARCH INSTITUTE (US) | 2007-12-13 | — | — | WO | disclosed |
| US-4140016-A | CHOLESTERIC LIQUID CRYSTAL THERMOMETERS, BENZOIC ESTER DERIVATIVES | BECTON, DICKINSON AND COMPANY (US) | 1979-02-20 | — | — | US | disclosed |
| US-4101207-A | Preparation of liquid crystal containing polymeric structure | OWENS-ILLINOIS, INC. (US) | 1978-07-18 | — | — | US | disclosed |
| US-3935337-A | Preparation of liquid crystal containing polymeric structure | OWENS-ILLINOIS, INC. (US) | 1976-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12576037-B2 | Polymer-encapsulated drug particles | PHOSPHO1, SGMS1, SGMS2 | POLA1 3432/4885CYP46A1 1580/4885OSBP 1530/4885 |
| US-12605342-B2 | Polymer-encapsulated drug particles | MUC1, SLC10A2, EGFR | POLA1 3846/4885CYP46A1 1706/4885OSBP 2135/4885 |
| US-20080089836-A1 | superparamagnetic nanoparticles of iron coated with bilayer of molecules:(a) layer of oleic acid in direct contact with the iron particles; (b) a layer of Tween\"; bilayer of surface binding molecules and amphiphatic molecules; self-assembles; solubilizing; reducing toxicity; gold in MRI and tomography | TFRC, FABP1, SCARB1 | POLA1 3799/4885CYP46A1 1065/4885OSBP 26/4885 |
| US-20250082582-A1 | POLYMER-ENCAPSULATED DRUG PARTICLES | CD47, GRPR, HSPA5 | POLA1 3852/4885CYP46A1 2046/4885OSBP 2017/4885 |
| US-20250213491-A1 | POLYMER-ENCAPSULATED DRUG PARTICLES | CD47, GRPR, HSPA5 | POLA1 3852/4885CYP46A1 2046/4885OSBP 2017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.